Introduction
============

Type 2 diabetes (T2D) is a progressive metabolic disease characterized by insulin resistance and pancreatic beta-cell dysfunction. The American Diabetes Association and European Association for the Study of Diabetes recommend initial treatment regimens consisting of diet and exercise, weight control, increased physical activity, smoking cessation, and lipid management, followed by metformin administration.[@b1-ppa-10-1539],[@b2-ppa-10-1539]

Metformin is an oral antidiabetic drug (OAD), and it is the most widely used first-line therapy in T2D treatments.[@b3-ppa-10-1539],[@b4-ppa-10-1539] The progressive nature of T2D warrants the use of other agents, such as sulfonylureas (SUs), thiazolidinediones, dipeptidyl peptidase-4 (DPP-4) inhibitors, glucagon-like peptide-1 receptor agonists, sodium--glucose cotransporter-2 inhibitors, or insulin, either as monotherapy or in addition to metformin.[@b1-ppa-10-1539],[@b2-ppa-10-1539]

Adherence to and persistence with OAD agents such as SUs and DPP-4 inhibitors are often suboptimal, and discontinuation rates are high. Studies document that treatment adherence in patients with T2D is often poor due to complicated treatment regimens, medication costs, and tolerability issues; better adherence is often associated with fewer daily doses of medications.[@b5-ppa-10-1539]--[@b9-ppa-10-1539]

Furthermore, in a retrospective analysis comparing adherence and persistence in patients treated with SUs or DPP-4 inhibitors, 41% of SU-treated and 47% of DPP-4 inhibitor-treated patients were adherent during the 1-year follow-up.[@b10-ppa-10-1539] A greater percentage of patients in the SU cohort (52%) discontinued treatment in comparison to the DPP-4 inhibitor cohort (45%).[@b10-ppa-10-1539] Similar results were observed for the 2-year follow-up.[@b10-ppa-10-1539] The results of Rathmann et al[@b11-ppa-10-1539] were comparable to these results considering that 49% of SU-treated and 39% of DPP-4 inhibitor-treated patients had discontinued treatment by the 24-month follow-up. As there are many possible treatment pathways for T2D given the array of drugs available, it is important to understand use patterns not only in terms of combination therapies but also with respect to different treatment pathways.

In this study, we attempt to compare adherence to and persistence with SUs and DPP-4 inhibitors as an augmentation after metformin monotherapy. In addition, this study examines how patients progress through treatment pathways after discontinuing second-line OAD by following treatment dispositions for 24 months thereafter. With the continuing follow-up (or observation) of patients' treatment regimens after discontinuation of the index OAD for up to 2 years, this study describes the progression of therapy, including alternative OAD regimens and injectable therapies. Treatment patterns observed from this study may be helpful for clinicians when considering treatment options for patients with T2D.

Methods
=======

This retrospective observational study utilized insurance claims data to compare patients who were prescribed SUs or DPP-4 inhibitors. Data for this analysis were collected from the Truven Health Analytics MarketScan^®^ Commercial Claims and Encounters database for the period 2009--2013 and the Medicare Supplemental and Coordination of Benefits database. These databases represent the health services of \~195 million employees, dependents, and retirees in the USA with primary or Medicare supplemental coverage through privately insured fee-for-service, point-of-service, or capitated health plans. The data collected from the databases are generally representative of the treated population in the USA. All enrollment records and drug claims were collected for the SU and DPP-4 inhibitor cohorts described herein.

For each cohort ([Figure 1](#f1-ppa-10-1539){ref-type="fig"}), eligible patients were those who initiated at least one prescription fill of the index drug (SU or the two DPP-4 inhibitors saxagliptin and sitagliptin, but not both index drugs) since January 1, 2010, to December 31, 2010 (index event period) with background metformin therapy; had ≥1 diagnoses of T2D; were ≥18 years old at the index date (date on which index drug was initiated) and had 24 months (12 months prior to and 12 months after index date) continuous pharmaceutical and medical benefit enrollment; and had ≥30 days of total supply for the index drug. Background metformin therapy was defined as evidence of possession of metformin prescription at the start or during the index period and also having at least one metformin claim within 6 months after index end date. Eligible patients did not have a prescription claim for the index drug for the previous 90 days in each respective cohort, in addition to not having type 1 diabetes, secondary diabetes, or gestational conditions during the baseline period (12 months prior to the index date).

The outcome measures were persistence, as measured by days to discontinuation of index drug, and adherence, as measured by proportion of days covered (PDC). Patients were considered to have discontinued treatment if the gap between the end date of a prior index drug claim and start date of a current index drug claim was ≥60 days. Patients who had not discontinued at the last day of postindex follow-up (12 months, counted as 365 days after the index start date) were censored at this time point. PDC was defined as the proportion of days that the patient had the index drug supply on hand during the 365-day follow-up period. The PDC provides a composite measure of both adherence prior to discontinuation and persistence during the entire follow-up period. It is generally accepted that patients with PDC of ≥80% are adherent.[@b12-ppa-10-1539] This is retrospective database study. The database has been de-identified and anonymized data that is HIPAA compliant was used; therefore, patient consent and ethical approval were not obtained.

Statistical analysis
--------------------

Propensity score matching was used to control for possible selection bias. Logistic regression was used to estimate the propensity score with the baseline variables capturing demographics, comorbidities and disease burden, comedication, region, insurance plan, and economic status. A greedy 1:1 matching algorithm[@b13-ppa-10-1539] was utilized to match each SU-treated patient with a similar DPP-4 inhibitor-treated patient.

Baseline characteristics of the SU and DPP-4 inhibitor cohorts were summarized and compared using the Wilcoxon rank sum test for continuous variables and chi-square test for categorical variables. Kaplan--Meier estimates and Cox regression were used to describe and compare, respectively, the persistence of patients in each cohort. *T*-tests were used to analyze the PDC, and the chi-square test was used to analyze adherence defined as achieving ≥80% PDC.

Results
=======

Prior to executing propensity score matching, there were 19,621 and 7,484 patients in the SU and DPP-4 inhibitor cohorts, respectively ([Figure 1](#f1-ppa-10-1539){ref-type="fig"}). [Table 1](#t1-ppa-10-1539){ref-type="table"} provides the baseline characteristics before and after propensity score matching. A majority of the baseline variables showed a significant (*P*\<0.05) difference between the cohorts before matching, and showed no significant difference after matching. Although the number of antidiabetic drug classes and unique antidiabetic generic drug names remained significant after matching, the mean and standard deviation (SD) of both variables were close. This difference was probably driven by the large sample size and does not confer clinical significance. Standardized differences[@b13-ppa-10-1539] in percentages were also calculated for these two variables, which indicated a good match for the number of antidiabetic drug classes (8.1%) and the number of antidiabetic medications (9.8%). The final number of patients in each matched propensity cohort was 6,758 ([Table 1](#t1-ppa-10-1539){ref-type="table"}).

[Figure 2A and B](#f2-ppa-10-1539){ref-type="fig"} shows the persistence rates of the SU and DPP-4 inhibitor cohorts before and after propensity score matching, respectively. Prior to propensity matching, 46.2% (9,064 of 19,621) and 52.1% (3,900 of 7,484) of SU- and DPP-4 inhibitor-treated patients, respectively, remained persistent during the 12-month follow-up period ([Figure 2A](#f2-ppa-10-1539){ref-type="fig"}). The hazard ratio of discontinuation for DPP-4 inhibitors versus SU before matching was 0.846 (*P*\<0.001) ([Figure 2A](#f2-ppa-10-1539){ref-type="fig"}), ie, the DPP-4 inhibitor cohort was \~15.4% less likely to discontinue the index drug. Following propensity matching, 48.0% (3,241 of 6,758) and 52.5% (3,550 of 6,758) of SU-and DPP-4 inhibitor-treated patients, respectively, remained persistent during the 12-month follow-up period ([Figure 2B](#f2-ppa-10-1539){ref-type="fig"} and [Table 2](#t2-ppa-10-1539){ref-type="table"}). The hazard ratio of discontinuation for DPP-4 inhibitors versus SU after matching was 0.877 (*P*\<0.001) ([Figure 2B](#f2-ppa-10-1539){ref-type="fig"}), ie, the DPP-4 inhibitor cohort was \~12.3% less likely to discontinue the index drug.

A summary of postmatching adherence as measured by PDC during the 12-month follow-up period is provided in [Table 2](#t2-ppa-10-1539){ref-type="table"}. The PDC results (mean \[SD\]) showed slightly better adherence for the DPP-4 inhibitor cohort (65.5 \[28.7\]) in comparison to the SU cohort (63.3 \[29.7\]). This difference was statistically significant when evaluated using a two-sample *t*-test (*P*\<0.001). The PDC of OAD and overall antidiabetic medication were similar in both cohorts. A higher percentage of patients in the DPP-4 inhibitor cohort (43.4% \[2,930\]) met the PDC threshold of ≥80% (good adherence) of the index drug compared to the SU cohort (40.5% \[2,736\]) ([Table 2](#t2-ppa-10-1539){ref-type="table"}). Comparing the good adherence to OAD and overall antidiabetic drugs, a similar percentage of patients in the SU cohort met the PDC threshold of ≥80% compared to the DPP-4 inhibitor cohort ([Table 2](#t2-ppa-10-1539){ref-type="table"}).

[Table 3](#t3-ppa-10-1539){ref-type="table"} provides a dynamic summary of the antidiabetic treatment regimens for up to 24 months for patients who discontinued their index drug. Of note, there was a high percentage of patients who did not initiate any antidiabetic medication following discontinuation of their index drug; a greater proportion of the SU cohort patients remained untreated. About 40% of patients resumed their index drug within 3 months of discontinuation. SU-treated patients were more likely to initiate metformin monotherapy, whereas DPP-4 inhibitor-treated patients were more likely to initiate combination OAD therapy after index drug discontinuation. Switching to the other combination therapy (SU + metformin vs DPP-4 inhibitor + metformin) or moving to three-OAD combination therapy was infrequent. Patients in the SU cohort were more likely to initiate insulin therapy, whereas patients in the DPP-4 inhibitor cohort were more likely to initiate therapy with noninsulin injectables. However, the initiation of injectable therapy was minimal after index drug discontinuation for both cohorts.

Discussion
==========

The results of this retrospective study show slightly better adherence (*P*\<0.001) and persistence (*P*\<0.001) for DPP-4 inhibitor use than for SU. Although the differences observed were statistically significant, the differences may be too small to warrant clinical implications. Our results are similar to prior reports that support better adherence to and persistence with DPP-4 inhibitors than for SUs.[@b10-ppa-10-1539],[@b11-ppa-10-1539]

The adherence results may be attributed to differences in the mechanisms of action of the drugs and the observed adverse side effects. The DPP-4 inhibitor agents are part of the incretin system medications, which increase the secretion of glucagon-like peptide-1 and gastric inhibitory peptide hormones by the small intestine.[@b14-ppa-10-1539] Agents in this class are able to mimic the "incretin effect", a greater insulin response after an oral glucose administration versus intravenous glucose administration.[@b14-ppa-10-1539] As suggested by Mishriky et al,[@b15-ppa-10-1539] DPP-4 inhibitors tend to be associated with less risk of hypoglycemia and weight gain in comparison to SUs. Considering this, patients in the DPP-4 inhibitor cohort may have experienced better treatment outcomes (less risk of hypoglycemia and minimal adverse events), resulting in better adherence compared to their SU counterparts. In addition, Doggrell and Warot[@b16-ppa-10-1539] suggest that better adherence is associated with better glycemic control (lower hemoglobin A1c \[HbA1c or glycated Hb\] levels), but caution should be exercised while considering the impact of race/ethnicity and low income on glycemic control. Better adherence to OAD agents may also be achieved by improving treatment regimens to avoid/limit adverse side effects, prescribing agents with easier-to-use formulations and less dosing frequency, and use of better approaches by clinicians in treating individual patients.[@b17-ppa-10-1539]

Our results also indicate that during the 24 months after discontinuation, as many as 40.7% and 42.0% of SU- and DPP-4 inhibitor-treated patients, respectively, resumed their index drug in combination with metformin. A general increase (SU:15.9%--21.1%; DPP-4 inhibitor: 14%--18.8%) in the percentage of patients not taking any agents was observed throughout the 24-month discontinuation follow-up period for both cohorts. Additionally, many patients did not switch to alternative OAD agents.

Another interesting finding of this study is that patients did not generally progress to use of more than two OADs, insulin, or noninsulin injectables in the 24 months after discontinuation. This may be attributed to the metformin background therapy for both cohorts. Rascati et al[@b18-ppa-10-1539] found that patients in the SU/thiazolidinedione cohort were 40% more likely to progress to insulin use compared to patients in the metformin/thiazolidinedione cohort. Their study also showed no significant difference between the SU and thiazolidinedione cohorts with metformin background therapy. Moreover, progression to noninsulin injectables was minimal, as also found in our study.

In sum, our results may be indicative of patient preferences for route of administration, dosing frequency, side effects, and other characteristics related to overall treatment regimen satisfaction with OAD use. Individual patients may have different needs and preferences, such as avoidance of weight gain, the risk of hypoglycemia, or medication costs, which play a role in their adherence to treatment regimens. More research is needed to understand the factors associated with medication selection, as well as adherence and persistence, and the reasons for which patients discontinue medications. Insufficient evidence exists to explore and evaluate 1) the high percentage of patients in this study who withdrew all antidiabetic medications and 2) the ways to improve medication adherence.

Limitations
-----------

In this study, HbA1c data were not available to evaluate the association between treatment outcomes and drug selection. Additional limitations are those common to most claims database studies. The claims database uses a standard set of medical care claims elements for items such as patient demographics and diagnosis/procedural codes, which may limit full patient profiling. Other limitations in the claims data include whether or not patients used medications as prescribed and reasons for discontinuation (financial hardship, no refill prescribed/available, etc).

Conclusion
==========

This study evaluated adherence to and persistence with SUs and DPP-4 inhibitors in combination with metformin in propensity-matched cohorts. Additionally, treatment dispositions beyond discontinuation were captured over a 24-month period after discontinuation. While the study confirms differences in persistence and adherence among patients treated with the comparison drugs, it is noteworthy that there is a continuing and measurable gap in the knowledge about and research on adherence to both OAD and other treatments over longer periods.
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![Flow diagram for patient selection.\
**Note:** ^a^Two years' continuous enrollment includes 1 year prior to and 1 year postindex date.\
**Abbreviations:** DPP-4, dipeptidyl peptidase-4; SU, sulfonylurea; T1D, type 1 diabetes; T2D, type 2 diabetes.](ppa-10-1539Fig1){#f1-ppa-10-1539}

![Pre- and postmatched persistence rates for SU versus DPP-4 inhibitors.\
**Notes:** Figure shows the persistence rate of the SU and DPP-4 inhibitor cohorts (**A**) before and (**B**) after propensity score matching. ^a^Represents the number of patients (%) who continued the index drug.\
**Abbreviations:** DPP-4, dipeptidyl peptidase-4; SU, sulfonylurea.](ppa-10-1539Fig2){#f2-ppa-10-1539}

###### 

Pre- and postmatched baseline characteristics and demographics

  Variable[a](#tfn1-ppa-10-1539){ref-type="table-fn"}   Prematched      Postmatched                                            
  ----------------------------------------------------- --------------- -------------- --------- -------------- -------------- ---------
  **Demographics**                                                                                                             
  Age, years                                            56.6 (12.1)     54.8 (11.1)    \<0.001   54.3 (11.4)    54.6 (11.1)    0.064
  Females                                               8,492 (43.3)    3,507 (46.9)   \<0.001   3,121 (46.2)   3,113 (46.1)   0.890
  Region                                                                                                                       
   North--Central                                       5,100 (26.0)    1,680 (22.5)   \<0.001   1,588 (23.5)   1,545 (22.9)   0.664
   Northeast                                            1,851 (9.4)     1,007 (13.5)             905 (13.4)     899 (13.3)     
   South                                                8,522 (43.4)    3,849 (51.4)             3,447 (51.0)   3,444 (51.0)   
   West                                                 4,120 (21.0)    940 (12.6)               812 (12.0)     862 (12.8)     
   Unknown                                              28 (0.1)        8 (0.1)                  6 (0.1)        8 (0.1)        
  **Comorbidities/complications**                                                                                              
  Neurological symptoms                                 2,547 (13.0)    879 (11.8)     0.006     805 (11.9)     789 (11.7)     0.670
  Peripheral vascular disease                           1,401 (7.1)     497 (6.6)      0.150     401 (5.9)      444 (6.6)      0.127
  Cardiovascular disease                                12,315 (62.8)   4,667 (62.4)   0.538     4,163 (61.6)   4,211 (62.3)   0.395
  Renal complications                                   2,914 (14.9)    1,121 (15.0)   0.793     1,020 (15.1)   1,010 (15.0)   0.810
  Endocrine/metabolic complications                     9,459 (48.2)    3,891 (52.0)   \<0.001   3,526 (52.2)   3,501 (51.8)   0.667
  Ophthalmic complications                              3,926 (20.0)    1,429 (19.1)   0.091     1,231 (18.2)   1,256 (18.6)   0.579
  Other complications                                   3,143 (16.0)    1,022 (13.7)   \<0.001   931 (13.8)     933 (13.8)     0.960
  Depression                                            1,048 (5.3)     362 (4.8)      0.095     336 (5.0)      327 (4.8)      0.720
  Obesity                                               1,382 (7.0)     462 (6.2)      0.011     395 (5.8)      429 (6.5)      0.222
  Osteoarthritis                                        1,886 (9.6)     760 (10.2)     0.178     648 (9.6)      665 (9.8)      0.622
  **Medications**                                                                                                              
  Number of antidiabetic drug classes                   1.2 (0.7)       1.0 (0.6)      \<0.001   0.9 (0.7)      0.9 (0.6)      \<0.001
  Number of any medications                             8.7 (5.5)       8.9 (5.6)      0.098     8.6 (6.0)      8.6 (5.4)      0.059
  Number of antidiabetic medications                    1.1 (0.7)       0.9 (0.5)      \<0.001   0.8 (0.6)      0.9 (0.5)      \<0.001
  **Other**                                                                                                                    
  Plan type                                                                                                                    
   FFS                                                  4,157 (21.2)    1,397 (18.7)   \<0.001   1,198 (17.7)   1,232 (18.2)   0.167
   HMO                                                  3,945 (20.1)    933 (12.5)               809 (12.0)     868 (12.8)     
   PPO                                                  11,050 (56.3)   4,962 (66.3)             4,558 (67.5)   4,492 (66.5)   
   Missing                                              469 (2.4)       192 (2.6)                193 (2.9)      166 (2.5)      
   CCI score                                            1.6 (1.2)       1.6 (1.1)      \<0.001   1.5 (1.1)      1.6 (1.1)      0.243

**Note:**

Data presented as n (%) for categorical variables and mean (SD) for numeric variables.

**Abbreviations:** CCI, Charlson Comorbidity Index; DPP-4, dipeptidyl peptidase-4; FFS, fee for service; HMO, health maintenance organization; PPO, preferred provider organization.

###### 

Postmatched adherence and persistence during the 12-month follow-up

                                                                      Sulfonylurea (N=6,758)   DPP-4 inhibitor (N=6,758)   *P*-value[a](#tfn3-ppa-10-1539){ref-type="table-fn"}
  ------------------------------------------------------------------- ------------------------ --------------------------- ------------------------------------------------------
  **Persistence, n (%)[b](#tfn4-ppa-10-1539){ref-type="table-fn"}**                                                        
  Index drug                                                          3,241 (48.0)             3,550 (52.5)                \<0.001
  **PDC,[c](#tfn5-ppa-10-1539){ref-type="table-fn"} mean (SD)**                                                            
  SU class                                                            63.3 (29.7)              3.9 (13.5)                  \<0.001
  DPP-4 inhibitor class                                               2.3 (10.2)               65.5 (28.7)                 \<0.001
  Antidiabetic drug (any)                                             77.5 (24.0)              77.1 (23.3)                 0.268
  Oral antidiabetic drug (any)                                        77.1 (24.3)              76.5 (23.6)                 0.188
  Noninsulin antidiabetic injectables                                 0.5 (4.4)                0.9 (5.8)                   \<0.001
  Insulin (any)                                                       1.1 (6.4)                0.8 (5.6)                   0.005
  **PDC threshold** ≥**80%, n (%)**                                                                                        
  SU class                                                            2,736 (40.5)             20 (0.3)                    \<0.001
  DPP-4 inhibitor class                                               13 (0.2)                 2,930 (43.4)                \<0.001
  Antidiabetic drug (any)                                             4,047 (59.9)             3,966 (58.7)                0.156
   Oral antidiabetic drug (any)                                       4,000 (59.2)             3,901 (57.7)                0.084

**Notes:**

*P*-value was calculated from the comparison of the time to discontinuation (nonpersistence) by log-rank test.

Persistence denotes the number of patients who continued treatment during the 12-month follow-up period.

PDC is the sum of the days that were covered during the 12-month follow-up period, divided by 365 days and multiplied by 100%. The thresholds represent the percentage of patients who met the PDC threshold of ≥80% during the 12-month follow-up period. All data are presented as n (%) or mean (SD).

**Abbreviations:** DPP-4, dipeptidyl peptidase-4; PDC, proportion of days covered; SD, standard deviation; SU, sulfonylurea.

###### 

Treatment progression patterns at 6-month intervals following discontinuation of index drug

  Drug class                      Sulfonylurea (N=2,529)   DPP-4 inhibitor (N=2,331)                                                                            
  ------------------------------- ------------------------ --------------------------- -------------- ------------ -------------- -------------- -------------- --------------
  None                            417 (16.5)               401 (15.9)                  483 (19.1)     534 (21.1)   356 (15.3)     327 (14.0)     409 (17.5)     439 (18.8)
  1\. OAD                         898 (35.5)               767 (30.3)                  738 (29.2)     739 (29.2)   670 (28.7)     592 (25.4)     584 (25.1)     590 (25.3)
   MET                            765 (30.2)               577 (22.8)                  504 (19.9)     468 (18.5)   606 (26.0)     495 (21.2)     435 (18.7)     424 (18.2)
   SU                             107 (4.2)                155 (6.1)                   180 (7.1)      204 (8.1)    24 (1.0)       34 (1.5)       66 (2.8)       75 (3.2)
   DPP-4 inhibitor                18 (0.7)                 25 (1.0)                    43 (1.7)       53 (2.1)     31 (1.3)       54 (2.3)       72 (3.1)       85 (3.6)
   Other                          8 (0.3)                  10 (0.4)                    11 (0.4)       14 (0.6)     9 (0.4)        9 (0.4)        11 (0.5)       6 (0.3)
  2\. OADs                        1,089 (43.1)             1,167 (46.1)                1,064 (42.1)   963 (38.1)   1,146 (49.2)   1,141 (49.0)   1,036 (44.4)   1,000 (42.9)
   MET + SU                       970 (38.4)               1,029 (40.7)                898 (35.5)     815 (32.2)   131 (5.6)      133 (5.7)      134 (5.7)      142 (6.1)
   MET + DPP-4 inhibitor          73 (2.9)                 84 (3.3)                    100 (4.0)      101 (4.0)    979 (42.0)     970 (41.6)     857 (36.8)     809 (34.7)
   Other                          46 (1.8)                 54 (2.1)                    66 (2.6)       47 (1.9)     36 (1.5)       38 (1.6)       45 (1.9)       49 (2.1)
  3\. OADs                        95 (3.8)                 155 (6.1)                   167 (6.6)      182 (7.2)    127 (5.4)      217 (9.3)      227 (9.7)      216 (9.3)
   Insulin (any)                  115 (4.5)                183 (7.2)                   229 (9.1)      298 (11.8)   88 (3.8)       127 (5.4)      171 (7.3)      211 (9.1)
   Insulin (only)                 25 (1.0)                 31 (1.2)                    61 (2.4)       92 (3.6)     17 (0.7)       27 (1.2)       41 (1.8)       56 (2.4)
   Insulin + MET                  76 (3.0)                 129 (5.1)                   131 (5.2)      151 (6.0)    59 (2.5)       72 (3.1)       99 (4.2)       119 (5.1)
   Insulin + SU                   43 (1.7)                 76 (3.0)                    89 (3.5)       101 (4.0)    11 (0.5)       18 (0.8)       25 (1.1)       40 (1.7)
   Insulin + DPP-4 inhibitor      16 (0.6)                 25 (1.0)                    26 (1.0)       37 (1.5)     28 (1.2)       40 (1.7)       65 (2.8)       62 (2.7)
   Noninsulin injectable (any)    47 (1.9)                 68 (2.7)                    86 (3.4)       100 (4.0)    99 (4.2)       125 (5.4)      140 (6.0)      149 (6.4)
   Noninsulin injectable (only)   4 (0.2)                  6 (0.2)                     14 (0.6)       15 (0.6)     12 (0.5)       21 (0.9)       30 (1.3)       27 (1.2)

**Note:** All data presented as n (%).

**Abbreviations:** DPP-4, dipeptidyl peptidase-4; MET, metformin; OAD, oral antidiabetic drug; SU, sulfonylurea.
